Terms: = Prostate cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
200 results:
1. Genomic analysis of primary epithelial neoplasms of the seminal vesicle identifies a subset of mucinous cystic tumours driven by kras mutations.
Collins K; Galea LA; Foroughi F; Siegmund SE; Anderson WJ; Appu S; Idrees MT; Ulbright TM; Acosta AM
Histopathology; 2024 Jun; 84(7):1192-1198. PubMed ID: 38409850
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer.
Ravi P; Freeman D; Thomas J; Ravi A; Mantia C; McGregor BA; Berchuck JE; Epstein I; Budde P; Ahangarian Abhari B; Rupieper E; Gajewski J; Schubert AS; Kilian AL; Bräutigam M; Zucht HD; Sonpavde G
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309723
[TBL] [Abstract] [Full Text] [Related]
3. Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells.
Dai X; Shi X; Luo M; Li P; Gao Y
BMC Cancer; 2023 Dec; 23(1):1241. PubMed ID: 38104097
[TBL] [Abstract] [Full Text] [Related]
4. Functional pri-miR-34b/c rs4938723 and kras 3'UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?
Vieira IA; Pezzi EH; Bandeira IC; Reis LB; de Araújo Rocha YM; Fernandes BV; Siebert M; Miyamoto KN; Siqueira MB; Achatz MI; Galvão HCR; Garcia FAO; Campacci N; Carraro DM; Formiga MN; Vianna FSL; Palmero EI; Macedo GS; Ashton-Prolla P
Gene; 2024 Mar; 898():148069. PubMed ID: 38070788
[TBL] [Abstract] [Full Text] [Related]
5. Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.
Jiagge E; Jin DX; Newberg JY; Perea-Chamblee T; Pekala KR; Fong C; Waters M; Ma D; Dei-Adomakoh Y; Erb G; Arora KS; Maund SL; Njiraini N; Ntekim A; Kim S; Bai X; Thomas M; van Eeden R; Hegde P; Jee J; Chakravarty D; Schultz N; Berger MF; Frampton GM; Sokol ES; Carrot-Zhang J
Cancer Cell; 2023 Nov; 41(11):1963-1971.e3. PubMed ID: 37890492
[TBL] [Abstract] [Full Text] [Related]
6. Bacterial lipopolysaccharide related genes signature as potential biomarker for prognosis and immune treatment in gastric cancer.
Yuan T; Zhang S; He S; Ma Y; Chen J; Gu J
Sci Rep; 2023 Sep; 13(1):15916. PubMed ID: 37741901
[TBL] [Abstract] [Full Text] [Related]
7. Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth.
Zhou Z; Jia D; Kwon O; Li S; Sun H; Roudier MP; Lin DW; True L; Morrissey C; Creighton CJ; Lee JK; Xin L
Oncogene; 2023 Aug; 42(32):2428-2438. PubMed ID: 37400528
[TBL] [Abstract] [Full Text] [Related]
8. AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.
Weng W; Meng T; Pu J; Ma L; Shen Y; Wang Z; Pan R; Wang M; Chen C; Wang L; Zhang J; Zhou B; Shao S; Qian Y; Liu S; Hu W; Meng X
Mol Cancer Ther; 2023 Sep; 22(9):1013-1027. PubMed ID: 37302522
[TBL] [Abstract] [Full Text] [Related]
9. prostate cancer genetic alterations in Hispanic men.
Arenas-Gallo C; Rhodes S; Garcia JA; Weinstein I; Prunty M; Lewicki P; Brant A; Basourakos SP; Barbieri CE; Lifschutz N; Schumacher FR; Shoag JE
Prostate; 2023 Sep; 83(13):1263-1269. PubMed ID: 37301735
[TBL] [Abstract] [Full Text] [Related]
10. Plexin-B1 Mutation Drives Metastasis in prostate cancer Mouse Models.
Shorning B; Trent N; Griffiths DF; Worzfeld T; Offermanns S; Smalley MJ; Williamson M
Cancer Res Commun; 2023 Mar; 3(3):444-458. PubMed ID: 36936664
[TBL] [Abstract] [Full Text] [Related]
11. Homologous recombination repair gene mutations in Malaysian prostate cancer patients.
Saeidi H; Raju CS; Ismail P; Raub SHA; Omar N; Hisyam Bakrin I
Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):22-26. PubMed ID: 36800845
[TBL] [Abstract] [Full Text] [Related]
12. MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q; Zhang S; Zhang H; Sun J; Lu J; Wang G; Wang X
Int Immunopharmacol; 2023 Mar; 116():109783. PubMed ID: 36773567
[TBL] [Abstract] [Full Text] [Related]
13. Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Varadi M; Nagy N; Reis H; Hadaschik B; Niedworok C; Modos O; Szendroi A; Ablat J; Black PC; Keresztes D; Csizmarik A; Olah C; Gaisa NT; Kiss A; Timar J; Toth E; Csernak E; Gerstner A; Mittal V; Karkampouna S; Kruithof de Julio M; Gyorffy B; Bedics G; Rink M; Fisch M; Nyirady P; Szarvas T
Cancer Med; 2023 Apr; 12(7):9041-9054. PubMed ID: 36670542
[TBL] [Abstract] [Full Text] [Related]
14. Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen.
Kukkonen K; Autio-Kimura B; Rauhala H; Kesseli J; Nykter M; Latonen L; Visakorpi T
Endocr Relat Cancer; 2022 Dec; 29(12):717-733. PubMed ID: 36219867
[TBL] [Abstract] [Full Text] [Related]
15. TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors.
Bacon JVW; Giannatempo P; Cataldo G; Fazli L; Saxena N; Ozgun G; Soleimani M; Chi K; Nichols C; Necchi A; Wyatt AW; Kollmannsberger CK; Nappi L
Oncologist; 2022 Nov; 27(11):e912-e915. PubMed ID: 36166584
[TBL] [Abstract] [Full Text] [Related]
16. Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes.
Karpova Y; Johnson SJ; Bordet G; Guo D; Ghatak A; Markov DA; Tulin AV
Biomed Pharmacother; 2022 Sep; 153():113504. PubMed ID: 36076593
[TBL] [Abstract] [Full Text] [Related]
17. Validation of a DNA-Based Next-Generation Sequencing Test for Molecular Diagnostic Variant and Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tissue Specimens and Liquid Biopsy Plasma/Cell-Free DNA Samples.
Werner TV; Kock S; Weber I; Kayser G; Werner M; Lassmann S
J Mol Diagn; 2022 Jul; 24(7):784-802. PubMed ID: 35787794
[TBL] [Abstract] [Full Text] [Related]
18. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
Bray AW; Duan R; Malalur P; Drusbosky LM; Gourdin TS; Hill EG; Lilly MB
Prostate; 2022 Sep; 82(13):1264-1272. PubMed ID: 35766303
[TBL] [Abstract] [Full Text] [Related]
19. Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes.
Kumar S U; Balasundaram A; Cathryn R H; Varghese RP; R S; R G; Younes S; Zayed H; Doss C GP
Comput Biol Med; 2022 Sep; 148():105701. PubMed ID: 35753820
[TBL] [Abstract] [Full Text] [Related]
20. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical prostate cancer Treatment: A Pan prostate cancer Group Study.
Burns D; Anokian E; Saunders EJ; Bristow RG; Fraser M; Reimand J; Schlomm T; Sauter G; Brors B; Korbel J; Weischenfeldt J; Waszak SM; Corcoran NM; Jung CH; Pope BJ; Hovens CM; Cancel-Tassin G; Cussenot O; Loda M; Sander C; Hayes VM; Dalsgaard Sorensen K; Lu YJ; Hamdy FC; Foster CS; Gnanapragasam V; Butler A; Lynch AG; Massie CE; ; Woodcock DJ; Cooper CS; Wedge DC; Brewer DS; Kote-Jarai Z; Eeles RA
Eur Urol; 2022 Aug; 82(2):201-211. PubMed ID: 35659150
[TBL] [Abstract] [Full Text] [Related]
[Next]
